The Efficacy And Safety Of Argatroban On Acute Cerebral Infarction

Objective: To assess the efficacy and safety of argatroban in treatment of acute cerebral infarctionMethods: 48 patients with acute cerebral infarction (ACI) were followed up in a double-blind, double-dummy, positive-controlled, with randomized study for 14 days. Sodium ozagrel was used as the control. Modifed Edinburgh-Scandinavian Stroke Scale (MESSS) and ability of daily living (ADL) score were used to evaluate efficacy of argatroban and ozagrel in the treatment of ACI. Results:1. 48 cases were randomly divided into argatroban group and ozagrel group. Patients' characters, history, initial symptoms MESSS and ADL had no significant difference.2. The scores of MESSS and ADL with argatroban had statistically greatly improved than the scores before curing (p<0.01). The results of ozagrel also showed a remarkable improvement in MESSS (p<0.05), but its ADL score hadno significant change (p>0.05).The effective rate of the two groups: The argatroban group is 91.67% and theozagrel group is 87.50%. The rate of the two groups had no significantdifference (p= 1.000).The two drugs are both effective to the treatment of ACI. Therapeuticevaluation of argatroban group is better than that of ozagrel group.3. Their blood and urine routine test, hepatic and renal function, heart rate,blood pressure, and ECG were all in normal state after curing. There were 21 patients showing adverse events in 48 cases, and their appearances were...